Last updated: February 20, 2026
What is the product associated with NDC 00003-5200?
NDC 00003-5200 refers to Remicade (Infliximab), a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis.
Market Overview
Current Market Size
The global infliximab market was valued at approximately $19 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of approximately 7% between 2023 and 2030. Market drivers include increasing prevalence of autoimmune disorders, expanded FDA approvals, and higher adoption of biosimilars.
Key Players
- Johnson & Johnson (Remicade)
- Celltrion (Inflectra/Remsima)
- Samsung Bioepis (Renflexis)
- Pfizer (Ixifi)
Patent expiry for Remicade in the US occurred in 2018, leading to biosimilar competition, which has affected pricing and market share.
Biosimilar Impact
Biosimilars entered the market in 2016, leading to significant price erosion. The therapeutic’s branded cost in the US ranges from $3,000 to $6,000 per infusion. Biosimilars are priced approximately 20-30% lower.
Usage and Treatment Trends
United States: The infliximab market accounts for ~30% of global inflammatory disease treatments. Annual treatment costs per patient:
- $20,000 to $25,000 for branded infliximab.
- Biosimilar adoption is increasing, especially in Medicaid and commercial plans.
Global: High-income countries dominate sales, but emerging markets exhibit rising demand due to healthcare access improvements.
Price Projections
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per 100 mg |
Biosimilar Price Reduction |
| 2018 |
$4,200 |
N/A |
| 2020 |
$3,700 |
~25% lower than brand |
| 2022 |
$3,500 |
Additional 10-15% drop |
Future Price Expectations
- 2023–2025: Continued biosimilar uptake could reduce prices by 15-25% for the remaining branded product.
- 2025–2030: Market penetration by biosimilars may lead to an additional 10-20% price reduction, with some biosimilars priced as low as $1,500–$2,000 per infusion.
Factors Influencing Price Trends
- Institutional and insurance formulary preferences.
- Patent litigation and exclusivity periods.
- Regulatory policy shifts, such as interchangeability rulings.
- Market entry of novel biologics or biosimilars further reducing prices.
Projected Price Range by 2030
| Year |
Estimated Average Wholesale Price (AWP) per 100 mg |
| 2023 |
$3,000–$3,500 |
| 2025 |
$2,800–$3,200 |
| 2030 |
$1,500–$2,000 |
Regulatory and Policy Drivers
- US FDA approved multiple biosimilars, starting with infliximab in 2016.
- Interchangeability standards are evolving, affecting substitution policies.
- European markets see more aggressive biosimilar adoption due to regulatory frameworks and pricing pressures.
Reimbursement Environment
- US: Medicare and Medicaid favor biosimilars, promoting lower reimbursement rates.
- Europe: Cost-effectiveness assessments lead to regional price caps.
- Emerging markets: Price sensitivity sustains demand for biosimilars.
Key Takeaways
- The infliximab market faces ongoing price declines driven by biosimilar competition.
- Prices are expected to decrease significantly by 2030, especially with broader biosimilar adoption.
- Market dynamics are influenced by regulatory policies, patent statuses, and payer preferences.
- Branded infliximab sales will diminish, but the product remains an essential therapy with steady demand.
- Companies investing in biosimilar development and market access strategies could realize substantial growth.
FAQs
1. How will biosimilar entry impact the clinical use of infliximab?
Biosimilars provide cost-effective alternatives, increasing overall usage due to reduced treatment costs and expanded access.
2. What are the main regions for infliximab market growth?
North America and Europe lead current sales; Asia-Pacific presents significant growth potential due to rising autoimmune disease prevalence and improving healthcare infrastructure.
3. How does patent expiry influence pricing?
Patent expiration typically results in biosimilar market entry, leading to price reductions of 20-30% or more in the following years.
4. Are there off-label uses affecting market size?
Yes, infliximab is used off-label for various inflammatory conditions, which can influence overall demand.
5. What regulatory changes could accelerate biosimilar adoption?
Policies that facilitate interchangeability approval, such as FDA back-end switching guidelines, can hasten biosimilar substitution and price reductions.
References
- IQVIA. (2022). Global biosimilars market report.
- U.S. Food and Drug Administration. (2016). Approval of infliximab biosimilars.
- Evaluate Pharma. (2023). Biopharma Market Trends.
- European Medicines Agency. (2022). Biosimilar medicines.
- Medicaid and Medicare Policy Analysis, 2022.
